Cutler Group LP Catalyst Pharmaceuticals, Inc. Transaction History
Cutler Group LP
- $307 Million
- Q1 2024
A detailed history of Cutler Group LP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Cutler Group LP holds 4,400 shares of CPRX stock, worth $92,268. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,400Holding current value
$92,268% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CPRX
# of Institutions
383Shares Held
99.5MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$392 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$178 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$116 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$71.8 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$65.8 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.16B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...